G6PD and cancer: Along these lines, several studies reported that NRF2 overexpression and/or the somatic mutations take place in many human cancers, including HCC, for a review see [94], and, remarkably, a very high frequency of Nrf2 somatic mutations associated with increased G6PD expression occurs at early stages of hepatocarcinogenesis in the DENA+CMD model [84,95].